Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of the prognostic index for spine metastasis (PRISM) for stratifying survival in patients treated with spinal stereotactic body radiation.
Florez MA, De B, Kowalchuk R, Tang C, Bishop AJ, Kouzy R, Amini B, Briere T, Beckham TH, Wang C, Li J, Tatsui CE, Rhines LD, Brown PD, Merrell K, Ghia AJ. Florez MA, et al. Among authors: kouzy r. Radiother Oncol. 2024 Dec;201:110570. doi: 10.1016/j.radonc.2024.110570. Epub 2024 Oct 2. Radiother Oncol. 2024. PMID: 39362605
Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials.
Sherry AD, Lin TA, McCaw ZR, Beck EJ, Kouzy R, Abi Jaoude J, Passy AH, Miller AM, Kupferman GS, Fuller CD, Thomas CR Jr, Koay EJ, Tang C, Msaouel P, Ludmir EB. Sherry AD, et al. Among authors: kouzy r. Int J Radiat Oncol Biol Phys. 2024 Dec 1;120(5):1239-1244. doi: 10.1016/j.ijrobp.2024.05.033. Epub 2024 Sep 30. Int J Radiat Oncol Biol Phys. 2024. PMID: 39352322
In Reply to Akhtar et al.
Kouzy R, Ludmir EB, Hoffman KE, Jhingran A, Kuban DA. Kouzy R, et al. Pract Radiat Oncol. 2024 Sep-Oct;14(5):466-467. doi: 10.1016/j.prro.2024.05.002. Pract Radiat Oncol. 2024. PMID: 39218529 No abstract available.
Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation.
Lin TA, McCaw ZR, Koong A, Lin C, Abi Jaoude J, Patel R, Kouzy R, El Alam MB, Sherry AD, Noticewala SS, Fuller CD, Thomas CR Jr, Sun R, Lee JJ, Lin R, Yuan Y, Shyr Y, Meirson T, Ludmir EB. Lin TA, et al. Among authors: kouzy r. Clin Cancer Res. 2024 Oct 15;30(20):4791-4799. doi: 10.1158/1078-0432.CCR-24-0566. Clin Cancer Res. 2024. PMID: 39133081
Towards Treatment Effect Interpretability: A Bayesian Re-analysis of 194,129 Patient Outcomes Across 230 Oncology Trials.
Sherry AD, Msaouel P, Kupferman GS, Lin TA, Abi Jaoude J, Kouzy R, El-Alam MB, Patel R, Koong A, Lin C, Passy AH, Miller AM, Beck EJ, Fuller CD, Meirson T, McCaw ZR, Ludmir EB. Sherry AD, et al. Among authors: kouzy r. medRxiv [Preprint]. 2024 Jul 24:2024.07.23.24310891. doi: 10.1101/2024.07.23.24310891. medRxiv. 2024. PMID: 39108512 Free PMC article. Preprint.
Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials.
Beck EJ, Sherry AD, Florez MA, Kouzy R, Abi Jaoude J, Lin TA, Miller AM, Passy AH, Kupferman GS, Patel RR, Chino F, Higbie VS, Parseghian CM, Overman MJ, Minsky BD, Thomas CR Jr, Tang C, Msaouel P, Ludmir EB. Beck EJ, et al. Among authors: kouzy r. Cancer Res Commun. 2024 Aug 1;4(8):2183-2188. doi: 10.1158/2767-9764.CRC-24-0265. Cancer Res Commun. 2024. PMID: 39099199 Free PMC article.
49 results